Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Sarcoma 39Leiomyosarcoma 10Osteosarcoma 8Breast Neoplasms 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Neuroectodermal Tumors, Primitive, Peripheral 4Neoplasm Metastasis 4Melanoma 4Liposarcoma 4Histiocytoma, Malignant Fibrous 4Chondrosarcoma 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma, Synovial 3Salivary Gland Neoplasms 3Prostatic Neoplasms 3Hemangiosarcoma 3Esophageal Neoplasms 3Dermatofibrosarcoma 3Colorectal Neoplasms 3Bone Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma, Kaposi 2Rhabdomyosarcoma 2Recurrent Uterine Corpus Sarcoma 2Neuroblastoma 2

Interventions

Paclitaxel 1Gemcitabine 1Doxorubicin 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Endometrial Cancer × Docetaxel × Sarcoma × Clear all
NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
71 enrolled
GynecologicSarcoma

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡